Skip to content

A Clinical Trial of Saireito for the Prevention of High-Output Stoma in Patients with Temporary Ileostomy after Surgery for Ulcerative Colitis

A Clinical Trial of Saireito for the Prevention of High-Output Stoma in Patients with Temporary Ileostomy after Surgery for Ulcerative Colitis - SAILOR(SAIreito for ILeostomy Output Reduction) study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000060810
Enrollment
36
Registered
2026-05-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Saireito (Tsumura Saireito Extract Granules, TJ-114) will be administered orally at a dose of 9 g/day (3 g three times daily after meals) from postoperative day 2 (POD2) for 14 consecutive days. Conc

Sponsors

Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine,
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients diagnosed with ulcerative colitis (UC) undergoing total proctocolectomy (two- or three-stage surgery) with creation of a temporary ileostomy Age >=18 years at the time of informed consent Patients considered capable of oral intake according to the postoperative management protocol Patients who have provided written informed consent to participate in the study

Exclusion criteria

Exclusion criteria: History of hypersensitivity to Kampo medicines Patients judged to be unable to receive oral medication in the early postoperative period Severe hepatic dysfunction, severe heart failure, or other conditions judged inappropriate by the principal investigator Pregnant or breastfeeding women, or women who may be pregnant Any other condition deemed inappropriate for participation by the investigator

Design outcomes

Primary

MeasureTime frame
Incidence of early high-output stoma (HOS) within 21 days after surgery. Early HOS is defined as a stoma output of >1,500 mL/day for three consecutive days within 21 days postoperatively. Stoma output will be measured daily during hospitalization based on nursing records and electronic medical records.

Secondary

MeasureTime frame
Length of hospital stay Incidence of >20% decline in eGFR at 1 month postoperatively and immediately before stoma closure, compared with preoperative baseline Requirement for unplanned intravenous fluid administration within 21 days after surgery Readmission within 21 days after surgery Incidence of adverse events assessed according to CTCAE version 5.0

Countries

Japan

Contacts

Public ContactYusuke Sato

Nagoya University Graduate School of Medicine Division of Gastroenterological Surgery, Department of Surgery

sato.yusuke.a3@f.mail.nagoya-u.ac.jp0527442250

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026